COG Phase 2 Trial of XL184 (Cabozantinib); an Oral Small-Molecule Inhibitor of Multiple Kinases; in Children and Young Adults with Refractory Sarcomas; Wilms Tumor; and Other Rare Tumors Pediatric CIRB Active Available to Open